FindTrial
Sign In

First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-503084-15-00
Acronym
CoRe_CC-3
Enrollment
77
Registered
2023-11-22
Start date
2024-01-12
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progressive metastatic solid cancer after failure of established treatment options

Interventions

None listed

Sponsors

Deutsches Krebsforschungszentrum (DKFZ)
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: May 30, 2026